Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (1)
  • Open Access

    ARTICLE

    Regorafenib-Induced Hand–Foot Skin Reaction Is More Severe on the Feet Than on the Hands

    Yuma Nonomiya*, Takashi Yokokawa, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, Tomomi Takiguchi, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Takeru Wakatsuki, Kensei Yamaguchi, Yoshikazu Sugimoto*, Toshihiro Hama

    Oncology Research, Vol.27, No.5, pp. 551-556, 2019, DOI:10.3727/096504018X15291727589740

    Abstract Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand–foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib.… More >

Displaying 1-10 on page 1 of 1. Per Page